{
    "clinical_study": {
        "@rank": "143016", 
        "arm_group": [
            {
                "arm_group_label": "SA237", 
                "arm_group_type": "Experimental", 
                "description": "Subcutaneous SA237"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Subcutaneous placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this study is to evaluate the efficacy, safety, pharmacodynamic,\n      pharmacokinetic and immunogenic profiles of SA237 in patients with NMO and NMOSD"
        }, 
        "brief_title": "Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD", 
        "completion_date": {
            "#text": "November 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Neuromyelitis Optica (NMO)", 
            "NMO Spectrum Disorder (NMOSD)"
        ], 
        "condition_browse": {
            "mesh_term": "Neuromyelitis Optica"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. NMO or NMOSD\n\n          2. Age 12 to 74 years, inclusive at the time of informed consent.\n\n        Exclusion Criteria\n\n          1. Pregnancy or lactation.\n\n          2. Evidence of other demyelinating disease or progressive multifocal leukoencephalopathy\n             (PML).\n\n          3. Known active infection (excluding fungal infections of nail beds or caries dentium)\n             within 4 weeks prior to baseline."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "74 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "70", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02028884", 
            "org_study_id": "SA-307JG", 
            "secondary_id": "2013-003752-21"
        }, 
        "intervention": {
            "arm_group_label": "SA237", 
            "intervention_name": "SA237", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 25, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Kansai region", 
                    "country": "Japan"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multicenter, Randomized, Addition to Baseline Treatment, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of SA237 in Patients With Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)", 
        "overall_contact": {
            "email": "clinical-trials@chugai-pharm.co.jp", 
            "last_name": "Clinical trials information"
        }, 
        "overall_contact_backup": {
            "email": "sa237@chugai-pharm.co.jp", 
            "last_name": "SA237 Clinical trial"
        }, 
        "overall_official": {
            "affiliation": "Chugai Pharmaceutical", 
            "last_name": "Akinori Yamada", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Time to first relapse", 
            "safety_issue": "No", 
            "time_frame": "up to approximately 30 months from first patient in"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02028884"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Annualized relapse rate", 
            "safety_issue": "No", 
            "time_frame": "up to approximately 30 months from first patient in"
        }, 
        "source": "Chugai Pharmaceutical", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Chugai Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}